{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:49:08Z","timestamp":1791888548593,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.amepre.2018.04.030","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T06:26:47Z","timestamp":1528957607000},"page":"244-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"55","author":[{"given":"Gibril J.","family":"Njie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna Bamrah","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yelk","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth N.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey S.","family":"Borisov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2018.04.030_bib1","series-title":"Global Tuberculosis Report 2016","year":"2016"},{"issue":"10","key":"10.1016\/j.amepre.2018.04.030_bib2","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"suppl 4 pt 2","key":"10.1016\/j.amepre.2018.04.030_bib3","first-page":"S221","article-title":"Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amepre.2018.04.030_bib4","series-title":"Ending Neglect: The Elimination of Tuberculosis in the United States","author":"Geiter","year":"2000"},{"issue":"8","key":"10.1016\/j.amepre.2018.04.030_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1164\/rccm.200510-1563OC","article-title":"The scope and impact of treatment of latent tuberculosis infection in the United States and Canada","volume":"173","author":"Sterling","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amepre.2018.04.030_bib6","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"issue":"4","key":"10.1016\/j.amepre.2018.04.030_bib7","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.amepre.2018.04.030_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.amepre.2018.04.030_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1016\/j.amepre.2018.04.030_bib10","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2018.04.030_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amepre.2018.04.030_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"48","key":"10.1016\/j.amepre.2018.04.030_bib13","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1)(suppl","key":"10.1016\/j.amepre.2018.04.030_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0749-3797(99)00119-1","article-title":"Developing an evidence-based Guide to Community Preventive Services\u2014methods","volume":"18","author":"Briss","year":"2000","journal-title":"Am J Prev Med"},{"issue":"1)(suppl","key":"10.1016\/j.amepre.2018.04.030_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0749-3797(99)00122-1","article-title":"Data collection instrument and procedure for systematic reviews in the Guide to The Community Preventive Services","volume":"18","author":"Zaza","year":"2000","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.amepre.2018.04.030_bib16","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.amepre.2018.04.030_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.amepre.2018.04.030_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta\u2010analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.amepre.2018.04.030_bib19","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0. Updated March 2011. The Cochrane Collaboration. http:\/\/training.cochrane.org\/handbook."},{"issue":"7109","key":"10.1016\/j.amepre.2018.04.030_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"issue":"10","key":"10.1016\/j.amepre.2018.04.030_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.amepre.2018.04.030_bib22","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"10.1016\/j.amepre.2018.04.030_bib23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/INF.0000000000001164","article-title":"Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatric tuberculosis infection","volume":"35","author":"Cruz","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.amepre.2018.04.030_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/TP.0b013e3182a94a2f","article-title":"Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates","volume":"97","author":"de Castilla","year":"2014","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.amepre.2018.04.030_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/INF.0000000000001151","article-title":"School-based study to identify and treat adolescent students at risk for tuberculosis infection","volume":"35","author":"Hatzenbuehler","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"34","key":"10.1016\/j.amepre.2018.04.030_bib26","doi-asserted-by":"crossref","first-page":"e4126","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.amepre.2018.04.030_bib27","doi-asserted-by":"crossref","first-page":"ofv220","DOI":"10.1093\/ofid\/ofv220","article-title":"Completion rate and side-effect profile of three-month isoniazid and rifapentine treatment for latent tuberculosis infection in an urban county jail","volume":"3","author":"Juarez-Reyes","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.amepre.2018.04.030_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s15010-017-1004-5","article-title":"Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates","volume":"45","author":"Knoll","year":"2017","journal-title":"Infection"},{"issue":"4","key":"10.1016\/j.amepre.2018.04.030_bib29","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1353\/hpu.2015.0126","article-title":"Improving treatment completion rates for latent tuberculosis infection: a review of two treatment regimens at a community health center","volume":"26","author":"Lines","year":"2015","journal-title":"J Health Care Poor Underserved"},{"issue":"146","key":"10.1016\/j.amepre.2018.04.030_bib30","first-page":"1","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.amepre.2018.04.030_bib31","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.amepre.2018.04.030_bib32","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000001329","article-title":"Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates","volume":"101","author":"Simkins","year":"2017","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.amepre.2018.04.030_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City health department clinics","volume":"62","author":"Stennis","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.amepre.2018.04.030_bib34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.amepre.2018.04.030_bib35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.amepre.2018.04.030_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and Isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"31","key":"10.1016\/j.amepre.2018.04.030_bib37","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.amepre.2018.04.030_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.amepre.2018.04.030_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15585\/mmwr.mm6511a2","article-title":"Leveling of tuberculosis incidence\u2014United States, 2013\u20132015","volume":"65","author":"Salinas","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.amepre.2018.04.030_bib40","doi-asserted-by":"crossref","first-page":"0039","DOI":"10.1128\/microbiolspec.TNMI7-0039-2016","article-title":"Treatment of latent tuberculosis infection","volume":"5","author":"Haley","year":"2017","journal-title":"Microbiol Spectr"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718317379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718317379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:51:12Z","timestamp":1760082672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379718317379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0749379718317379"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2018.04.030","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2018.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine","name":"copyright","label":"Copyright"}]}}